ArticleClinical endoscopy2019
Fecal Microbiota Transplantation: An Update on Clinical Practice.
Article in Clinical endoscopy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and trial sequential analysis.European journal of medical research · 2024Pooled it
- Alternative treatment of recurrentFrontiers in microbiology · 2024Pooled it
- Fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials.Frontiers in medicine · 2022Pooled it
- Is there a role of faecal microbiota transplantation in reducing antibiotic resistance burden in gut? A systematic review and Meta-analysis.Annals of medicine · 2021Pooled it
- A systematic review on the role of microbiota in the pathogenesis and treatment of eating disorders.European psychiatry : the journal of the Association of European Psychiatrists · 2020Pooled it
- Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Microbiome-based therapeutics forGut microbes · 2026Review
- Fecal Microbiota Transplantation BeyondJournal of Korean medical science · 2026Review
- [Gut-brain-joint axis in rheumatoid arthritis: from microeco-logical disturbance to multi-target synergy].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- How the gut microbiome affects the immunotherapy response in hepatocellular carcinoma.Cancer biology & medicine · 2026Review
- Review
- Push Enteroscopic Jejunal and Ileoscopic Delivery of Fecomicrobiota Transplantation (FMT) for Treatment ofJGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Science of fecal microbiota transplant: From history to cutting-edge clinical practice.World journal of gastrointestinal endoscopy · 2026Review
- Fecal microbiota and microbial community transplantation:Frontiers in microbiology · 2026Review
- The selection of matching donors for patients in fecal microbiota transplantation.Frontiers in microbiology · 2026Review
- Addressing Unmet Needs inCurrent medicinal chemistry · 2026Review
- Decoding the Gut-Brain Axis in Alzheimer's Disease: Emerging Perspectives.CNS & neurological disorders drug targets · 2026Review
- Osteoarthritis as a systemic disorder: multi-organ crosstalk in pathogenesis and therapeutic targeting.Frontiers in immunology · 2026Review
- Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy.Molecular cancer · 2025Review
- Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy.Drug discovery today · 2025Review
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fecal microbiota transplantation (FMT) is an infusion in the colon, or the delivery through the upper gastrointestinal tract, of stool from a healthy donor to a recipient with a disease believed to be related to an unhealthy gut microbiome. FMT has been successfully used to treat recurrent Clostridium difficile infection (rCDI). The short-term success of FMT in rCDI has led to investigations of its application to other gastrointestinal disorders and extra-intestinal diseases with presumed gut dysbiosis. Despite the promising results of FMT in these conditions, several barriers remain, including determining the characteristics of a healthy microbiome, ensuring the safety of the recipient with respect to long-term outcomes, adequate monitoring of the recipient of fecal material, achieving high-quality control, and maintaining reasonable costs. For these reasons, establishing uniform protocols for stool preparation, finding the best modes of FMT administration, maintaining large databases of donors and recipients, and assuring that oral ingestion is equivalent to the more widely accepted colonoscopic infusion are issues that need to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.